2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.
Sara A. Hurvitz, MD, associate professor, David Geffen School of Medicine, University of California, Los Angeles (UCLA), medical oncologist, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director, Santa Monica-UCLA Outpatient Oncology Practices, director, Breast Cancer Clinical Trials Program, UCLA, discusses the rationale for the phase 3 DESTINY-Breast03 trial (NCT03529110) examining in HER2-positive breast cancer.
Data from DESTINY-Breast03 clinical trial were first presented as part of an interim analysis, evaluating fam-trastuzumab deruxtecan-nxki (Enhertu) vs ado-trastuzumab emtansine (T-DM1; Kadcyla) in patients who had received at least 1 prior line of trastuzumab and taxane-based therapy and had experienced disease progression, according to Hurvitz.
This study, which included more than 500 patients, was aimed to compare the progression-free survival and overall survival of the 2 drugs, Hurvitz concludes.